Highest-materiality recent filing
Krystal Biotech Q2 2026 revenue $119.2M (+24% YoY); net income $54.8M; cash $1.1B
Q2 2026 VYJUVEK global revenue $119.2M, up 24% YoY; gross margin 95%.
Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates
VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.
Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111
Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.
Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030
Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.
Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).
Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches
Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.
Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit
Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.
Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue
VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.
Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa
Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.
PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.
Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis
First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.
Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%
27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).
KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.
Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured
VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.
Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025
EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.
Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025
CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.
Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M
Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).
Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC
ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.
KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.
Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan
Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.
94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.
Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track
VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.
Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M
Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.
Krystal Biotech reports Q4 net product revenue of $42.1M from VYJUVEK; net income of $8.7M
Net product revenue $42.1M in Q4 2023; $50.7M full year 2023; gross margin 93% in Q4.
Krystal Biotech reports first VYJUVEK revenue of $8.6M; net income $80.7M in Q3 2023
VYJUVEK net product revenue $8.6M in Q3 2023; 284 Patient Start Forms from 136 prescribers; patient compliance 96%.
Krystal Biotech reports Q2 2023 net loss $33.2M; VYJUVEK launch yields 121 patient start forms
VYJUVEK approved May 19; 121 Patient Start Forms submitted in first six weeks of launch.
Krystal Biotech expands to oncology; FDA accepts IND for KB707 for solid tumors
FDA accepted IND for KB707, a modified HSV-1 vector delivering IL-12 and IL-2 for solid tumors.
Krystal Biotech raises $160M in PIPE at $92.50/share for VYJUVEK launch and pipeline
Sold 1,729,729 shares at $92.50 each to institutional investors; gross proceeds ~$160M.
FDA approves Krystal Biotech's VYJUVEK gene therapy for DEB; first redosable gene therapy
FDA approval of VYJUVEK (beremagene geperpavec-svdt) for dystrophic epidermolysis bullosa (DEB) patients aged 6 months+.
Krystal Biotech presents long-term B-VEC data showing durable wound healing in DEB patients
DDEB patient treated >2 years and RDEB patient >3 years with weekly topical B-VEC.
Krystal Biotech Q1 net loss $45.3M, cash $355.5M, PDUFA date May 19 for B-VEC
Net loss of $45.3M ($1.76 per share) vs $50.0M loss ($1.99) in Q1 2022.
Krystal Biotech reports FY2022 net loss $140M; B-VEC PDUFA date May 19, 2023
Cash, cash equivalents and investments $383.8M at Dec 31, 2022.
Krystal Biotech receives 3-month FDA BLA review extension for B-VEC; new PDUFA date May 19, 2023
FDA extended PDUFA date for B-VEC (beremagene geperpavec) to May 19, 2023 due to major amendment from manufacturing info.
Krystal Biotech subsidiary Jeune reports up to 9-month durability for KB301 in PEARL-1 extension
Up to nine months durability of effect observed in patients aged 55-76 following high dose KB301.
Krystal Biotech Q3 net loss $29.9M; B-VEC BLA with Priority Review accepted, PDUFA Feb 17, 2023
Cash and investments $407M at quarter end; net loss $29.9M ($1.17 per share) vs $15.6M loss in Q3 2021.
KB407 CF gene therapy data: human CFTR expression 106–440% of endogenous in NHPs; IND accepted
KB407 transduced ciliated, club, and goblet cells in NHP airways; no transduction of basal cells.
FDA accepts Krystal Biotech's BLA for B-VEC with Priority Review; PDUFA Feb 2023
FDA accepted BLA for B-VEC (gene therapy) to treat dystrophic epidermolysis bullosa (DEB).
Krystal Biotech Q2 net loss widens to $28.1M; BLA filed for B-VEC, KB407 IND accepted
Q2 net loss $28.1M ($1.10/share) vs $16.4M loss YoY; cash $438.5M.
Andrew Orth, the Company’s Chief Commercial Officer, notified the Company that he was resigning from his position and his last day with the Company was August 2, 2023.
On March 6, 2023, the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”) approved an increase in the size of the Board from eight (8) directors to nine (9) directors and appointed Catherine Mazzacco as an independent member of the Board to fill the vacancy created by the increase in the size of the Board.
Effective February 25, 2022, the board of directors of the Company appointed Ms. Suma M. Krishnan, the Company's current Chief Operating Officer, as the Company's President, R&D.
On January 13, 2022, the Board appointed E. Rand Sutherland as a member of the Board, effective January 18, 2022, to fill the vacancy created by Dr. Marantz’s resignation.
Dr. Marantz will continue to serve as a director of the Company until January 18, 2022, subsequent to which, she has agreed to commence a senior executive position (Chief Business Officer) at the Company.
On January 12, 2022, Jing Marantz gave notice of her resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).
Max materiality 0.95 · Median 0.75 · Most common event other_material